5 Key Takeaways
-
1
Two-year phase 1/2 PRISM data for intravitreal 4D-150 in neovascular AMD showed stable central subfield thickness and best-corrected visual acuity.
-
2
Dr. Sheth reported that 4D-150 reduced supplemental injection requirements over 2 years, including among patients with recalcitrant disease.
-
3
Among recalcitrant patients, 22% received no injections and nearly 59% received 2 or fewer supplemental treatments over 2 years.
-
4
Among more recently diagnosed patients, 66% received no supplemental treatments and nearly 90% received 2 or fewer injections over 2 years.
-
5
The trial and phase 3 study use 20 weeks of topical steroids after treatment, with drops tapered over that period.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
